Chemo Tied to Long-Lasting Physical Health Decline for Breast Cancer Survivors
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 5, 2025 -- Breast cancer (BC) survivors who receive chemotherapy may experience greater physical health decline than those who receive endocrine therapy alone, according to a study published online Feb. 28 in JAMA Network Open.
Clara Bodelon, Ph.D., from the American Cancer Society in Atlanta, and colleagues conducted a prospective cohort study of participants in 35 states, the District of Columbia, and Puerto Rico between 2006 and 2013 to examine physical health decline in BC survivors who received chemotherapy or endocrine therapy compared with age-matched women without cancer. Data were included for 2,566 women diagnosed with BC and 12,826 women without cancer.
Of the women with BC, 47.7, 10.8, and 24.7 percent received endocrine therapy, chemotherapy, and both, respectively. The researchers found greater physical health decline within two years of diagnosis for BC survivors receiving endocrine therapy, chemotherapy, or both (β = −1.12, −3.13, and −3.26, respectively). The decline among endocrine therapy users was only seen in women receiving aromatase inhibitors. More than two years after diagnosis, only women who received chemotherapy experienced a decline in physical health.
"Understanding the survivorship care needs and management of late effects in BC survivors is critical," the authors write. "Continued efforts are needed to understand the specific survivorship care needs of BC survivors and improve their long-term quality of life."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Helping Others Linked to Higher Level of Cognitive Function
THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...
TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical...
Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes
THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.